Download PDF
Hamostaseologie 2007; 27(05): 333-337
DOI: 10.1055/s-0037-1617000
Original Article
Schattauer GmbH

Direkte Thrombininhibition in der interventionellen Kardiologie

Die ACUITY-StudieDirect thrombin inhibition in interventional cardiologyThe ACUITY trial
H. Heinze
1   Klinik für Kardiologie und konservative Intensivmedizin, Vivantes Klinikum Neukölln, Berlin
,
H. Darius
1   Klinik für Kardiologie und konservative Intensivmedizin, Vivantes Klinikum Neukölln, Berlin
› Author Affiliations
Further Information

Publication History

Publication Date:
27 December 2017 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Der direkte Thrombininhibitor Bivalirudin wurde im Rahmen der ACUITY-Studie bei 13 819 Patienten mit akutem Nicht-ST-Elevations-Koronarsyndrom prospektiv randomisiert untersucht. Dabei wurden drei antithrombotische Therapieregime im Rahmen eines frühinvasiven Vorgehens verglichen: Heparin plus Glykoprotein-IIb/IIIaRezerptorinhibitor (GPI), Bivalirudin plus GPI und Bivalirudin als Montherapie. Bezogen auf den Endpunkt der ischämischen Ereignisse war Bivalirudin allein vergleichbar mit Heparin plus GPI bei signifikant verringerter Rate von Blutungskomplikationen.

Summary

The direct thrombin inhibitor bivalirudin was tested in the ACUITY Trial 13 819 patients with acute non-ST-segment elevation coronary syndrome in a prospective and randomized design. Three therapeutic regimens were compared in the context of an early invasive strategy: heparin plus glycoprotein IIb/IIIa inhibitor (GPI), bivalirudin plus GPI, or bivalirudin alone. Concerning the rate of ischaemic events bivalirudin alone was comparable to heparin plus GPI at a significantly lower rate of bleeding complications.

Schlüsselwörter

Bivalirudin - akutes Koronarsyndrom - ACUITY - Blutungskomplikationen

Keywords

Bivalirudin - acute coronary syndrome - ACUITY - bleeding complications
 

  • Literatur

  • 1 European Society of Cardiology.. Guidelines for the treatment of acute coronary syndrome. European Heart Journal Advance Access published June 14, 2007.
    PubMedGoogle Scholar
  • 2 Lincoff AM, Bittl JA, Harrington RA. et al. Bivalirudin and provisional glycoproteinIIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIablockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289: 853-863 1638.
    CrossrefPubMedGoogle Scholar
  • 3 Lincoff AM, Kleiman NS, Kereiakes DJ. et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoproteinIIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 2004; 292: 696-703 JAMA 2006; 296-46.
    CrossrefPubMedGoogle Scholar
  • 4 Stone GW, Bertrand M, Colombo A. et al. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. Am Heart J 2004; 148: 764-775.
    CrossrefPubMedGoogle Scholar
  • 5 Stone GW, McLaurin BT, Cox DA. et al. ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355: 2203-2216.
    CrossrefPubMedGoogle Scholar
  • 6 Stone GW, White HD, Ohmann EM. et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 2007; 369: 907-919.
    CrossrefPubMedGoogle Scholar
  • 7 Stone GW, Bertrand ME, Moses JW. et al. Routine Upstream Initiation vs Deferred Selective Use of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes. The Acuity Timing Trial. JAMA 2007; 297: 591-602.
    CrossrefPubMedGoogle Scholar
  • 8 Stone GW, Hamon M. Authors Reply. N Engl J Med 2007; 356: 10.
    CrossrefPubMedGoogle Scholar
  • 9 Hamm CW. Leitlinien: Akutes Koronarsyndrom (ACS) Teil 1: ACS ohne persistierende ST-Hebung. Z Kardiol 2004; 93: 72-90.
    CrossrefPubMedGoogle Scholar